Laura Lee Sandler, serving as Chief Operating Officer for Oruka Therapeutics, Inc. (NASDAQ: ORKA), disclosed the divestment of common stock valued at approximately $472,078 on July 1, 2026. The transaction involved shares sold at prices ranging between $93.29 and $95.51. Simultaneously, Sandler purchased 5,000 additional shares by exercising employee warrants priced at $7.80 per share, resulting in a total acquisition cost of $39,000.
The execution of this sale occurred while ORKA shares were trading close to their 52-week high of $97.78. The biopharmaceutical company has experienced a substantial 640% increase in stock value over the preceding twelve months. According to InvestingPro analysis, the current market valuation positions ORKA among the most overvalued equities relative to its estimated fair value. The stock has appreciated 208% year-to-date, prompting further examination of its valuation metrics and insider activity patterns.
The disposition of 5,000 common shares was conducted through multiple transactions governed by a Rule 10b5-1 trading plan established on September 19, 2025. The breakdown of the sale reveals specific pricing tiers: 2,237 shares were sold at a weighted average price of $93.8457, with individual transaction prices ranging from $93.29 to $94.26. An additional 2,263 shares were sold at a weighted average price of $94.7458, with prices between $94.38 and $95.19. The remaining 500 shares were sold at a weighted average price of $95.472, with prices ranging from $95.40 to $95.51.
The concurrent acquisition of 5,000 common shares resulted from the exercise of employee warrants. These warrants carried an exercise price of $7.80 per share and followed a vesting schedule where 1/4 of the underlying shares vested on April 3, 2025, with 1/48 of the underlying shares vesting monthly thereafter. Following these reported transactions, Ms. Sandler directly holds 236,384 shares of Oruka Therapeutics common stock and 79,996 employee warrants.
Recent market developments for Oruka Therapeutics include several analyst updates and strategic initiatives. UBS increased its price target for Oruka Therapeutics to $130, citing optimism regarding upcoming efficacy data expected to demonstrate improved results compared to earlier studies. H.C. Wainwright reiterated its Buy rating and a $120 price target following AbbVie’s acquisition of Apogee Therapeutics, which may impact Oruka’s competitive landscape. Piper Sandler reaffirmed an Overweight rating with a $180 price target after Oruka amended its license agreement with Paragon Therapeutics. This amendment allows Oruka and Syre to pursue new therapeutic areas with IL-23s, enhancing their development pipeline.
Additionally, Oruka presented positive trial data from its EVERLAST-A study, demonstrating significant efficacy in treating moderate-to-severe psoriasis. Analysts have generally maintained a positive outlook on Oruka, with expectations of continued advancements in their therapeutic offerings. The stock currently trades at $93.27, reflecting a decline of $1.900 or 2.00% from the previous close. After-hours trading shows further movement with a price of $88.92, down $4.370 or 4.68%.